Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wendy T Parker

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Pathology|September 2, 2011
Molecular methods in diagnosis and monitoring of haematological malignanciesDavid T Yeung, Wendy T Parker, Susan Branford
Bioinformatics (Oxford, England)|May 7, 2016
BAM-matcher: a tool for rapid NGS sample matchingPaul P S Wang, Wendy T Parker, Susan Branford, et al.
Blood|January 3, 2012
Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profileWendy T Parker, Musei Ho, Hamish S Scott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2011
Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapyWendy T Parker, Rebecca M Lawrence, Musei Ho, et al.
Leukemia & Lymphoma|July 2, 2011
Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathwaysCarine Tang, Lisa Schafranek, Dale B Watkins, et al.
Bioinformatics (Oxford, England)|July 12, 2013
A comparative analysis of algorithms for somatic SNV detection in cancerNicola D Roberts, R Daniel Kortschak, Wendy T Parker, et al.
Blood|January 17, 2016
The impact of multiple low-level BCR-ABL1 mutations on response to ponatinibWendy T Parker, David T O Yeung, Alexandra L Yeoman, et al.
Blood Advances|January 4, 2018
<i>ASXL1</i> and <i>BIM</i> germ line variants predict response and identify CML patients with the greatest risk of imatinib failureJustine E Marum, David T Yeung, Leanne Purins, et al.
Blood|May 27, 2014
Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 declineSusan Branford, David T Yeung, Wendy T Parker, et al.
Pathology|August 28, 2022
Novel modes of MPL activation in triple-negative myeloproliferative neoplasmsSaumya E Samaraweera, Tatjana Geukens, Debora A Casolari, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Pathology|September 2, 2011
Molecular methods in diagnosis and monitoring of haematological malignanciesDavid T Yeung, Wendy T Parker, Susan Branford
Bioinformatics (Oxford, England)|May 7, 2016
BAM-matcher: a tool for rapid NGS sample matchingPaul P S Wang, Wendy T Parker, Susan Branford, et al.
Blood|January 3, 2012
Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profileWendy T Parker, Musei Ho, Hamish S Scott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2011
Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapyWendy T Parker, Rebecca M Lawrence, Musei Ho, et al.
Leukemia & Lymphoma|July 2, 2011
Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathwaysCarine Tang, Lisa Schafranek, Dale B Watkins, et al.
Bioinformatics (Oxford, England)|July 12, 2013
A comparative analysis of algorithms for somatic SNV detection in cancerNicola D Roberts, R Daniel Kortschak, Wendy T Parker, et al.
Blood|January 17, 2016
The impact of multiple low-level BCR-ABL1 mutations on response to ponatinibWendy T Parker, David T O Yeung, Alexandra L Yeoman, et al.
Blood Advances|January 4, 2018
<i>ASXL1</i> and <i>BIM</i> germ line variants predict response and identify CML patients with the greatest risk of imatinib failureJustine E Marum, David T Yeung, Leanne Purins, et al.
Blood|May 27, 2014
Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 declineSusan Branford, David T Yeung, Wendy T Parker, et al.
Pathology|August 28, 2022
Novel modes of MPL activation in triple-negative myeloproliferative neoplasmsSaumya E Samaraweera, Tatjana Geukens, Debora A Casolari, et al.
Pageof 2